Picture of BioNTech SE logo

BNTX — BioNTech SE Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeLarge CapContrarian

Momentum

Relative Strength (%)
1m+4.65%
3m+10.64%
6m-48%
1yr-17.41%
Volume Change (%)
10d/3m-28.81%
Price vs... (%)
52w High-66.67%
50d MA-3.5%
200d MA-33.18%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)5.49
PEG Ratio (f)n/a
EPS Growth (f)-27.66%
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value2.21
Price to Tang. Book2.24
Price to Free Cashflow6.93
Price to Sales1.51
EV to EBITDA1.62

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital111.73%
Return on Equity139.59%
Operating Margin78.85%

Financial Summary

Year End 31st DecUnit201720182019202020212022E2023ECAGR / Avg
Total Revenue€m61.6127.58108.59482.3218,976.716,219.539,828.68318.95%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%n/an/an/an/a+65351.47-17.64-45.92n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of BioNTech SE EPS forecast chart

Profile Summary

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. It develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Directors

Last Annual
December 31st, 2021
Last Interim
March 31st, 2022
Incorporated
January 1st, 2008
Public Since
October 10th, 2019
No. of Employees
3,082
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Select Market
Shares in Issue
242,521,489

BNTX Share Price Performance

Upcoming Events for BNTX

BioNTech SE Annual Shareholders Meeting

Dividend For B1NT34.SA - 1.3232 BRL

Dividend For BNTX.OQ - 2.1110 USD

Q2 2022 BioNTech SE Earnings Release

Q2 2022 BioNTech SE Earnings Call

Q3 2022 BioNTech SE Earnings Release

Q3 2022 BioNTech SE Earnings Call

Similar to BNTX

Picture of 2Seventy Bio logo

2Seventy Bio

us flag iconNASDAQ Global Select Market

Picture of 4D Molecular Therapeutics logo

4D Molecular Therapeutics

us flag iconNASDAQ Global Select Market

Picture of AbCellera Biologics logo

AbCellera Biologics

us flag iconNASDAQ Global Select Market

Picture of AbSci logo

AbSci

us flag iconNASDAQ Global Select Market

Picture of ACADIA Pharmaceuticals logo

ACADIA Pharmaceuticals

us flag iconNASDAQ Global Select Market

FAQ

Or unlock with your email

Or unlock with your email